FOXO1 and type 2 diabetes mellitus: A recent study on glucose and lipid metabolism exploiting farnesoid X receptor agonists [119] highlights the mechanism of gluconeogenesis suppression by the miR-22/PI3K/AKT/FOXO1 pathway in T2DM mice, through a decrease in miR-22 expression and an increase in FOXO1 levels.